How to Stop Opioid Cravings After Detox or Rehab
DeBinge opioid transition: When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
Opioid cravings can continue after detox or rehab even when a person is strongly committed to recovery. Withdrawal may have ended, but the brain can still respond to stress, pain, memories, people, places and routines that were previously associated with opioid use.
There is no single technique that can guarantee every opioid craving will disappear immediately. The strongest approach is usually to combine evidence-based treatment for opioid use disorder with a practical plan for managing triggers, changing the recovery environment, treating mental-health problems and responding quickly when cravings intensify.
Buprenorphine and methadone can directly reduce opioid cravings as part of treatment for opioid use disorder. Naltrexone works differently: it blocks opioid receptors and reduces or prevents opioid effects while adequate medication levels are present. The appropriate approach depends on the individual and should be determined through clinical assessment.
Related: For people who struggle with the opioid-free waiting period before naltrexone, see how a medically managed opioid-to-naltrexone transition can be approached.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This educational article has been prepared for clinical review. Until formal review has been completed, it should not be represented as medically reviewed.
View Dr Fergus Law’s professional profile
A Craving Is a Signal to Use the Recovery Plan
Cravings can be one of the most difficult parts of returning to everyday life after opioid detox or rehab.
During treatment, a person may be physically separated from the places, people and routines that previously surrounded opioid use. When they return home, many of those cues can reappear.
A craving may feel urgent, but feeling a craving does not mean the person has decided to use opioids or that treatment has failed.
It means something has activated the opioid-use pathway strongly enough that the recovery plan needs to respond.
Effective relapse prevention combines medical treatment, preparation, environmental changes, support and practical actions that reduce the opportunity for a craving to turn into opioid use.
In This Guide
- Why opioid cravings continue
- How long cravings can last
- What to do during a craving
- Identify craving triggers
- Change the environment
- Medication for opioid cravings
- Naltrexone and cravings
- Mental health, pain and sleep
- Daily craving-prevention plan
- When cravings need urgent attention
- Frequently asked questions
- Clinical sources
Why Do Opioid Cravings Continue After Detox?
Detoxification can reduce or resolve acute withdrawal, but withdrawal is only one part of opioid use disorder.
Repeated opioid use can become strongly connected with situations that occur before and during use. Those associations may remain after detox.
Stress
Work pressure, financial problems, arguments and emotional overload may recreate conditions previously connected with opioid use.
People
Contact with people associated with previous opioid use can reactivate powerful learned responses.
Places
A home, neighbourhood, street or other location can become strongly associated with obtaining or using opioids.
Pain
Physical pain may trigger thoughts about opioids, especially when opioids were previously used for relief.
Emotions
Anxiety, loneliness, anger, sadness or rejection can become connected with the expectation of opioid relief.
Routine
A certain time of day, payday, driving route or repeated daily sequence can act as a learned cue.
This is one reason detoxification alone is not recommended as complete treatment for opioid use disorder.
How Long Do Opioid Cravings Last After Detox or Rehab?
There is no single timeline that applies to everyone.
Some people notice that cravings become less frequent as recovery becomes more stable. Others experience intermittent cravings long after acute withdrawal has ended, particularly when a strong trigger appears.
The intensity of a craving can also change over time.
A person may feel relatively stable for days or weeks and then experience a strong craving after a stressful event, contact with an old opioid-using environment or another powerful cue.
A more useful question is whether the person has treatment and a practical response that prevents cravings from controlling behaviour.
Cravings that are persistent, increasing, interfering with daily functioning or repeatedly bringing the person close to opioid use deserve clinical review.
What to Do When a Strong Opioid Craving Starts
The best time to create a craving plan is when the person is relatively stable, not when the craving is already at its strongest.
A simple sequence can reduce the number of decisions that need to be made during a high-risk moment.
Leave the Trigger
Move away from the person, place or situation that is intensifying the craving where possible.
Reduce Access
Avoid contact with suppliers, opioid-using contacts or other immediate routes to obtaining opioids.
Contact Someone
Call a clinician, counsellor, recovery contact, family member or another trusted support person.
Delay the Decision
Do not treat the craving as a command that has to be acted on immediately.
Escalate Support
If cravings remain intense or the person is actively seeking opioids, contact the treatment team promptly.
Do not wait for opioid use to occur before increasing treatment support.
Identify Your Personal Opioid Craving Triggers
General information about triggers is useful, but relapse prevention becomes much more practical when the person identifies their own patterns.
Useful questions include:
- Where am I when cravings usually begin?
- Who am I usually speaking to?
- What emotion occurs just before the craving?
- Does pain trigger thoughts about opioids?
- Are cravings more common at a particular time of day?
- Does payday increase risk?
- Does alcohol or another drug make opioid use more likely?
- Do arguments trigger opioid thoughts?
- Does being alone increase risk?
- Which locations are most strongly connected with previous opioid use?
Once these patterns are identified, the response can be prepared in advance.
See the full section on opioid relapse triggers and early warning signs .
Change the Environment, Not Only the Thought
Trying to resist a craving while remaining in the same high-risk environment can make recovery unnecessarily difficult.
Environmental changes can reduce both the frequency of triggers and the opportunity to act on them.
Remove Easy Contact
Block or remove contacts whose primary connection is obtaining or using opioids.
Avoid High-Risk Locations
Where practical, change routes and routines that repeatedly expose the person to previous opioid-use environments.
Reduce Unstructured Time
Build predictable activity around periods that were previously associated with opioid use.
Increase Treatment Contact
More frequent contact may be appropriate when cravings or relapse risk begin to increase.
The aim is to remove unnecessary exposure to situations that repeatedly turn difficult feelings into immediate access to opioids.
Which Medications Can Help With Opioid Cravings?
The FDA has approved three medications for opioid use disorder: buprenorphine, methadone and naltrexone.
They work differently, so the question is not simply which medication is “strongest.” Treatment should be matched to the individual.
| Medication | How It Works | Relationship to Cravings | Important Point |
|---|---|---|---|
| Buprenorphine | Partial mu-opioid receptor agonist. | Can suppress and reduce opioid cravings and withdrawal. | Can be used as continuing OUD treatment under appropriate clinical supervision. |
| Methadone | Full mu-opioid receptor agonist. | Can reduce opioid cravings and withdrawal. | In the United States, methadone for OUD is generally provided through certified opioid treatment programs. |
| Naltrexone | Opioid receptor antagonist. | Works primarily by blocking opioid effects rather than acting as an opioid agonist. | Requires an appropriate opioid-free period before initiation to avoid precipitated withdrawal. |
Medication choice and transitions require individual clinical assessment.
The broader medication comparison is covered in medication options for preventing opioid relapse .
Does Naltrexone Stop Opioid Cravings?
Naltrexone should not be described as a medication that guarantees opioid cravings will disappear.
Its primary pharmacological role is opioid receptor blockade. When adequate medication levels are present, opioid effects can be blocked or substantially reduced.
For some patients, knowing that opioids are unlikely to produce the expected effects may change the behavioural context in which cravings occur. Individual craving experiences, however, vary.
This distinction is important because opioid relapse prevention involves more than whether a medication directly suppresses craving.
Counselling and recovery planning still need to address why the craving appeared and how the person responds to it.
Starting Naltrexone After Opioid Use
CDC guidance states that naltrexone should be started after an opioid-free period to avoid precipitating severe opioid withdrawal.
The exact timing should be determined clinically based on the opioids involved and the individual’s circumstances.
Naltrexone should never be treated as making opioid overdose impossible.
Long-Acting Naltrexone
Longer-acting formulations can reduce the need to make repeated daily decisions about taking medication.
That can be relevant where medication adherence is a major relapse vulnerability.
Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States. DeBinge treatment using long-acting implant-based naltrexone takes place in Nassau, The Bahamas, following individual assessment.
Read more: Long-Acting Naltrexone Implant .
Cravings Can Be Stronger When Other Problems Are Untreated
A craving may be the visible problem while something else is driving it.
Anxiety
If opioids were previously used to reduce anxiety or emotional tension, untreated anxiety can continue activating opioid thoughts.
Depression
Low mood, hopelessness and social withdrawal can weaken recovery routines and increase isolation.
Trauma
Trauma-related symptoms may need specific treatment rather than expecting abstinence alone to resolve them.
Pain
People with chronic or acute pain may need an individual pain-management plan that accounts for opioid-use-disorder history.
Sleep
Persistent sleep disruption can make stress and emotional regulation more difficult.
Other Substance Use
Alcohol or other drug use can reduce judgment and increase exposure to opioid-related environments.
Increasing cravings should therefore prompt the question: what has changed?
A Daily Plan for Reducing Opioid Craving Risk
Take prescribed treatment as directed
Do not repeatedly miss or alter medication without discussing the problem with the prescribing clinician.
Know the day’s vulnerable periods
Identify when cravings are most likely and arrange activity or support around those times.
Keep recovery contacts accessible
Do not wait until the craving becomes overwhelming before deciding whom to contact.
Reduce unnecessary exposure to triggers
Avoid repeating contact with people, places and routines that consistently increase opioid craving.
Attend counselling and clinical follow-up
Craving patterns can change, and treatment may need to change with them.
Watch for gradual deterioration
Sleep disruption, isolation, missed appointments and increasing thoughts about opioids can occur before a crisis.
Keep naloxone available
Overdose-prevention planning remains important wherever opioid exposure is possible.
When Are Opioid Cravings Becoming a Relapse Warning Sign?
A single craving does not necessarily mean that opioid use is about to occur.
Risk deserves more attention when several warning signs begin appearing together.
- cravings are becoming stronger or more frequent;
- the person is contacting previous opioid-using friends;
- previous suppliers are being contacted;
- high-risk locations are being revisited;
- counselling appointments are being missed;
- medication is being skipped or stopped;
- the person is becoming increasingly isolated;
- alcohol or other drug use is increasing;
- the person is beginning to believe opioid use can now be controlled;
- opioids are being actively searched for or obtained.
Treatment contact should be increased quickly and overdose precautions should be reviewed.
Why Opioid Cravings After Detox Can Be Especially Dangerous
Opioid tolerance can decrease during abstinence.
If a strong craving leads to opioid use after detox or rehab, an amount that was previously tolerated may now carry greater overdose risk.
That is why craving management and overdose prevention should not be separated.
Give naloxone if available, contact emergency services immediately and remain with the person until professional help arrives.
Learn more about overdose risk after opioid detox and reduced tolerance .
Craving Control Is One Part of Preventing Opioid Relapse
Opioid relapse prevention also involves medication, trigger planning, counselling, mental-health care, family support, overdose prevention, the recovery environment and a clear response if opioid use returns.
Read the complete DeBinge framework:
Discuss a Longer-Term Relapse-Prevention Plan
DeBinge provides addiction treatment in Nassau, The Bahamas. For suitable patients, a consultation may include discussion of long-acting naltrexone alongside counselling and continuing recovery planning.
Individual suitability depends on factors including current opioid use, detox status, medical history, previous treatment, medications and the person’s recovery goals.
Opioid Cravings After Detox or Rehab: FAQs
How do you stop opioid cravings after detox?
There is no single technique that guarantees immediate elimination of every craving. Evidence-based treatment may include medication for opioid use disorder, identifying triggers, reducing access to opioids, counselling, mental-health treatment and a prepared response for strong cravings.
Why do I still crave opioids after detox?
Detox addresses acute withdrawal, but learned associations, stress, pain, emotions, environmental cues and opioid-use-disorder symptoms can continue after withdrawal has ended.
Can opioid cravings come back after weeks without cravings?
Yes. Cravings can be intermittent and may reappear when a strong trigger such as stress, pain, a familiar person or a previous opioid-use environment occurs.
Which medication is best for opioid cravings?
There is no single medication that is best for every patient. Buprenorphine and methadone can reduce opioid cravings. Naltrexone works differently by blocking opioid receptors and opioid effects. Medication choice requires individual clinical assessment.
Does buprenorphine reduce opioid cravings?
Yes. CDC and SAMHSA describe buprenorphine as reducing or suppressing opioid cravings and withdrawal as part of treatment for opioid use disorder.
Does methadone reduce opioid cravings?
Yes. Methadone is a long-acting opioid agonist used in treatment of opioid use disorder and can reduce opioid cravings and withdrawal.
Does naltrexone completely stop opioid cravings?
It should not be presented as guaranteeing that cravings disappear. Naltrexone primarily blocks opioid receptors and reduces or prevents opioid effects while adequate medication levels are present. Individual craving experiences vary.
Can I start naltrexone immediately after using opioids?
No. Naltrexone requires an appropriate opioid-free period before initiation because starting it while significant opioid dependence remains can precipitate severe withdrawal.
Are naltrexone implants FDA-approved in the United States?
No. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.
What should I do if a craving becomes overwhelming?
Leave the triggering environment where possible, reduce access to opioids, contact a treatment or recovery support person and seek clinical help promptly if you are actively considering or preparing to use opioids.
What should I do if I use opioids again?
Address overdose safety first. If overdose is suspected, administer naloxone if available and contact emergency services. After immediate safety is addressed, reconnect with treatment quickly and review what contributed to the return to use.
Evidence Used in This Guide
CDC — Opioid Use Disorder: Treating
CDC guidance covering buprenorphine, methadone and naltrexone, opioid cravings, detoxification and continuing treatment.
FDA — Medications for Opioid Use Disorder
Current FDA information on approved medications used to treat opioid use disorder.
SAMHSA — Buprenorphine
SAMHSA information on buprenorphine treatment, including reduction of opioid withdrawal symptoms and cravings.
SAMHSA — Methadone
SAMHSA information on methadone treatment, including its role in reducing opioid cravings and withdrawal.
SAMHSA — Substance Use Disorder Treatment Options
Overview of medication and other treatment options for substance use disorders, including opioid use disorder.
SAMHSA — Coping and Support
General SAMHSA guidance on coping, support and maintaining physical and mental wellbeing during recovery.
Clinical recommendations, medication approvals and regulatory information can change. Patients should confirm current information with their treating clinician and the relevant healthcare regulator.
Related: For people who struggle with the opioid-free waiting period before naltrexone, see how a medically managed opioid-to-naltrexone transition can be approached.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an educational resource about opioid cravings, opioid-use-disorder treatment and relapse prevention. It is awaiting formal clinical approval.
View Dr Fergus Law’s professional profile
This Article Does Not Replace Individual Medical Care
This page provides general educational information and does not diagnose opioid use disorder, determine treatment suitability or recommend a specific medication for an individual.
Do not abruptly stop methadone, buprenorphine, prescribed opioids or another prescribed medication based on this article. Medication changes and transitions should be discussed with an appropriately qualified clinician.
Naltrexone should not be initiated while significant opioid physical dependence remains. Appropriate opioid-free preparation and clinical assessment are required.
If someone is unconscious, cannot be awakened, has very slow or stopped breathing, or an opioid overdose is suspected, administer naloxone if available and contact local emergency services immediately.
DeBinge is located in Nassau, The Bahamas. We do not operate a treatment facility in the United States. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.